文献速递艾滋病与性传播感染

每周四天抗逆转录病毒维持治疗:ANRS 162-4D 试验

Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trial.
PubMed 文献 · J Antimicrob Chemother · 2018-01-01

ANRS 162-4D 是一项 48 周多中心研究,纳入病毒学受控的 HIV-1 感染成人,采用每周连续 4 天服药、停药 3 天的维持方案。48 周时 96%(95%CI 90%-98%)的参与者仍在每周四天方案下维持 VL<50 copies/mL,3 例病毒学失败者恢复每日治疗后均再抑制,无严重治疗相关事件。

要点

  • VL<50 copies/mL 至少 1 年的成人可考虑每周四天维持方案
  • 48 周时 96% 参与者维持病毒学抑制且未脱离该策略
  • 病毒学失败者恢复每日治疗后均实现再抑制

核心结论

  • 每周四天抗逆转录病毒维持治疗在 48 周内对 96% 的患者有效,可能降低长期毒性、保持高依从性并节省药费。

研究设计与样本

  • 入组条件为 VL<50 copies/mL 至少 1 年,且正在接受含 PI/r 或 NNRTI 的三联治疗。
  • 方案为同一方案每周连续服药 4 天,随后停药 3 天;主要结局为第 48 周仍在该策略下且 VL<50 copies/mL 的参与者比例。
  • 研究设计为观察到成功率>90%,把握度 87%,5% Ⅰ类错误;注册号 ClinicalTrials.gov NCT02157311、EudraCT 2014-000146-29。

主要发现

  • 正在进行的方案含 PI/r 者 29 例,含 NNRTI 者 71 例。
  • 第 48 周时 96% 的参与者(95%CI 90%-98%)无失败且仍在每周四天方案下。
  • 3 例发生病毒学失败,均恢复每日治疗并实现再抑制;1 例停止该策略;无严重治疗相关事件。

关键数值与推荐

  • 主要结局阈值:第 48 周仍在该策略下且 VL<50 copies/mL 的参与者比例,设计预期观察到成功率>90%。
  • 第 48 周实际成功率为 96%(95%CI 90%-98%)。

临床怎么用

  • 对 VL<50 copies/mL 至少 1 年、正在接受含 PI/r 或 NNRTI 三联治疗的成人,可评估每周四天维持方案的适用性。
  • 实施中需监测 VL;出现病毒学失败时应恢复每日治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intermittent treatment could improve the convenience, tolerability and cost of ART, as well as patients' quality of life. We conducted a 48 week multicentre study of a 4-days-a-week antiretroviral regimen in adults with controlled HIV-1-RNA plasma viral load (VL). METHODS: Eligible patients were adults with VL < 50 copies/mL for at least 1 year on triple therapy with a ritonavir-boosted PI (PI/r) or an NNRTI. The study protocol consisted of the same regimen taken on four consecutive days per week followed by a 3 day drug interruption. The primary outcome was the proportion of participants remaining in the strategy with VL < 50 copies/mL up to week 48. The study was designed to show an observed success rate of > 90%, with a power of 87% and a 5% type 1 error. The study was registered with ClinicalTrials.gov (NCT02157311) and EudraCT (2014-000146-29). RESULTS: One hundred patients (82 men), median age 47 years (IQR 40-53), were included. They had been receiving ART for a median of 5.1 (IQR 2.9-9.3) years and had a median CD4 cell count of 665 (IQR 543-829) cells/mm3. The ongoing regimen included PI/r in 29 cases and NNRTI in 71 cases. At 48 weeks, 96% of participants (95% CI 90%-98%) had no failure while remaining on the 4-days-a-week regimen. Virological failure occurred in three participants, who all resumed daily treatment and became resuppressed. One participant stopped the strategy. No severe treatment-related events occurred. CONCLUSIONS: Antiretroviral maintenance therapy 4 days a week was effective for 48 weeks in 96% of patients, leading to potential reduction of long-term toxicities, high adherence to the antiretroviral regimen and drug cost saving.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. de Truchis P, Assoumou L, Landman R, et al. Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trial. J Antimicrob Chemother. 2018. PMID: 29186458. doi:10.1093/jac/dkx434

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。